Download presentation
Presentation is loading. Please wait.
Published byLesley Barber Modified over 6 years ago
1
The Role of Neutrophil Elastase Inhibitors in Lung Diseases
Eva Polverino, MD, PhD, Edmundo Rosales-Mayor, MD, Glenn E. Dale, PhD, Klaus Dembowsky, MD, PhD, Antoni Torres, MD, PhD CHEST Volume 152, Issue 2, Pages (August 2017) DOI: /j.chest Copyright © 2017 American College of Chest Physicians Terms and Conditions
2
Figure 1 Innate immune defense. α1-AT = alpha1 antitrypsin; MMP = matrix metalloproteinase; NE = neutrophil elastase; SLPI = secretory leukocyte protease inhibitor. CHEST , DOI: ( /j.chest ) Copyright © 2017 American College of Chest Physicians Terms and Conditions
3
Figure 2 Ratio and 90% CI of AZD9668 to placebo for changes in sputum inflammatory biomarkers. Compared with placebo, AZD9668 was associated with reductions in all sputum biomarkers (TNF-α, IL-6, IL-8, IL-1β, RANTES, MCP-1) except LTB4. Changes in IL-6 and RANTES were statistically significant. There were no changes in blood inflammatory biomarkers. LTB4 = leukotriene B4; MCP-1 = monocyte chemoattractant protein-1; RANTES = regulated on activation, normal T-cell expressed and secreted; TNF = tumor necrosis factor. (Adapted with permission from Elborn et al.57) CHEST , DOI: ( /j.chest ) Copyright © 2017 American College of Chest Physicians Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.